Solutions
For individual investors
Centralize your alternative investments and better measure investment performance.
For family offices & groups
Elevate your private investment operations with a modern secure solution.
For advisors and intermediaries
Impress asset owners with streamlined private investment management and reporting.
Company
PricingBlogSolutions
For individual investors
Centralize your alternative investments and better measure investment performance.
For family offices & groups
Elevate your private investment operations with a modern secure solution.
For advisors and intermediaries
Impress asset owners with streamlined private investment management and reporting.
Company
Charlottesville | NYC | Mexico City | Montevideo

Adenosine Therapeutics
Charlottesville, VA, USA
Founded January 1999
2 Employees
C Corporation
Medical Facilities and Services, Pharmaceuticals
Key People
Joel Linden
Executive
Robert Capon
Chairman & CEO
Description
Through an in-license agreement with the University of Virginia Patent Foundation, ATL was granted exclusive, worldwide rights to the University's adenosine-related patent portfolio, including apadenoson, developed as Stedivaze, a cardiac stress agent for use in diagnosis of coronary artery disease. Stedivaze was shepherded by ATL to the end of Phase II development before ATL sold substantially all its assets to Clinical Data, Inc. (CLDA) in 2008. CLDA and its successors carried on development into late Phase III.
Acquired by Clinical Data in 2008; operating status currently unknown.
Updates Feed
- Note LoremPublic
- Document Loremdocument.pdf1Public
- Announcement LoremPublic